Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key ...

Bernstein Liebhard LLP reminds Merck investors of an April 14, 2025 deadline to join a securities fraud class action lawsuit.

New York, New York-- (Newsfile Corp. - April 1, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, ...

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Oracle Corp.

Learn more about whether Jazz Pharmaceuticals plc or Merck & Co., Inc. is a better investment based on AAII's A+ Investor ...

Merck dazzled with Phase 3 trial results for its PAH drug WINREVAIR, but the market responded with a collective shrug, ...

Based on Wall Street analyst estimates for 2025 EPS, Amgen trades at 15 times its projected earnings, while Merck sits at a ...

When topline phase III data was released in November, hinting at the potential of success, Jefferies analyst Akash Tiwari ...

Despite this potential, the stock has fallen by 25% in the past 12 months -- so is it a bargain buy right now? During the ...

We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.